E H Gerlach - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

E H Gerlach

Showing results (71-80 of 85) with videos related to

Pageof 9

Sort By:

Diagnostic Microbiology and Infectious Disease|August 1, 1988

Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testingR N Jones, K E Aldridge, A L Barry, et al.

Journal of Clinical Microbiology|December 1, 1989

Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracyclineR N Jones, T L Gavan, C Thornsberry, et al.

Antimicrobial Agents and Chemotherapy|November 1, 1982

Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testingL W Ayers, R N Jones, A L Barry, et al.

The Journal of Antimicrobial Chemotherapy|September 1, 1985

Cefpiramide: comparative in-vitro activity and beta-lactamase stabilityA L Barry, R N Jones, C Thornsberry, et al.

Diagnostic Microbiology and Infectious Disease|August 1, 1992

Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelinesE H Gerlach, R N Jones, S D Allen, et al.

Journal of Clinical Microbiology|June 1, 1995

Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1G V Doern, R N Jones, E H Gerlach, et al.

Diagnostic Microbiology and Infectious Disease|September 1, 1991

Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelinesR N Jones, E H Gerlach, F P Koontz, et al.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 1, 1991

Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolatesP R Murray, S D Allen, M E Erwin, et al.

Antimicrobial Agents and Chemotherapy|July 1, 1991

In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolatesJ A Washington, R N Jones, S D Allen, et al.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 1, 1993

Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamineA L Barry, M A Pfaller, P C Fuchs, et al.

Pageof 9

Search research articles

Showing results (71-80 of 85) with videos related to

Sort By:

Pageof 9

Diagnostic Microbiology and Infectious Disease|August 1, 1988

Journal of Clinical Microbiology|December 1, 1989

Antimicrobial Agents and Chemotherapy|November 1, 1982

The Journal of Antimicrobial Chemotherapy|September 1, 1985

Cefpiramide: comparative in-vitro activity and beta-lactamase stabilityA L Barry, R N Jones, C Thornsberry, et al.

Diagnostic Microbiology and Infectious Disease|August 1, 1992

Journal of Clinical Microbiology|June 1, 1995

Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1G V Doern, R N Jones, E H Gerlach, et al.

Diagnostic Microbiology and Infectious Disease|September 1, 1991

Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelinesR N Jones, E H Gerlach, F P Koontz, et al.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 1, 1991

Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolatesP R Murray, S D Allen, M E Erwin, et al.

Antimicrobial Agents and Chemotherapy|July 1, 1991

In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolatesJ A Washington, R N Jones, S D Allen, et al.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 1, 1993

Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamineA L Barry, M A Pfaller, P C Fuchs, et al.

Pageof 9